Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
160.8 SAR | -2.55% |
|
-2.07% | -6.40% |
06-12 | Dallah Healthcare Maintains Q1 Dividend | MT |
05-15 | Dallah Healthcare Company Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Strengths
- The company returns high margins, thereby supporting business profitability.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company is in debt and has limited leeway for investment
- With an expected P/E ratio at 36.4 and 30.45 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Most analysts recommend that the stock should be sold or reduced.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.40% | 4.19B | - | ||
-32.87% | 13.6B | B+ | ||
-4.50% | 11.49B | B | ||
+10.33% | 10.78B | B+ | ||
+27.92% | 8.59B | B | ||
-9.39% | 7.29B | A- | ||
+8.16% | 6.85B | B- | ||
+7.51% | 6.41B | D | ||
+16.88% | 4.39B | B+ | ||
+36.60% | 4.22B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4004 Stock
- Ratings Dallah Healthcare Company